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INTRODUCTION
Cyclophosphamide (CY), an alkylating agent, is fre-
quently used in the treatment of various autoimmune
disorders and malignancies. Acute hyponatremia after
intravenous CY treatment is an infrequent but poten-
tially life-threatening complication. Development of
symptomatic hyponatremia is usually associated with
high-dose intravenous CY treatment and has rarely
been reported with low-dose treatment. Moreover,
only one case of symptomatic hyponatremia following
low- dose oral CY treatment has been reported so far
1). We report a patient with ANCA-positive glo-
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merulonephritis who developed severe symptomatic
hyponatremia following 3 weeks of oral CY (1.6 mg/kg/
day) administration.
CASE REPORT
A 68-year old woman who was treated for ANCA-
associated GN was admitted to the emergency depart-
ment (ED) due to nausea, vomiting and lethargy that
had persisted for several days. Six weeks before the
ED visit, she had previously been hospitalized in He-
matology Division for evaluation of anemia and fever
of unknown origin. During this admission period there
was a rapid increment in her serum creatinine from
0.75 mg/dL to 3.22 mg/dL. Further investigations re-
vealed positive anti-myeloperoxidase (750 AAU) and
anti-proteinase 3 (483 AAU) (normal cutoff for both
ANCA 150 AAU). She underwent percutaneous≤
renal biopsy which demonstrated multiple cellular
crescents and focal segmental glomerulosclerosis. She
was diagnosed as having ANCA-associated GN and
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3 days of methylprednisolone pulse therapy (750 mg/
day) was initiated. After the steroid pulse therapy, she
was given oral CY (100 mg/day) and oral prednisolone
(60 mg/day). Low dose oral loop diuretics and losartan
was given to control edema and proteinuria, respec-
tively. She initially tolerated her medications well and
was discharged from the hospital without any com-
plaints. At discharge, her serum creatinine level was
3.07 mg/dL and her serum sodium level was 137 mmol/
L. However, 3 weeks after discharge from the hospital
she complained of nausea, vomiting and severe lethargy
and visited ED.
At ED, she was confused and disoriented. Her blood
pressure was elevated to 150/90 mmHg and the pulse
rate was 72 beat per minute. Tongue was mildly dried
and skin turgor was also slightly decreased; however,
the patient showed no signs of pitting edema. Chest
X-ray demonstrated no signs of pulmonary edema or
significant decrease of heart size, which means there
was no significant decrease of volume status (Fig.
1). Serum sodium was decreased to 102 mmol/L with
decreased plasma osmolality (218 mOsm/kg) (re-
ference value 278-298 mOsm/kg), while urinary Na
excretion was 40 mmol/L with urinary osmolality of
238 mOsm/kg (reference value 50-1400 mOsm/kg).
Urinary creatinine was 32.5 mg/dL and fractional ex-
cretion of sodium was 3.7%. Laboratory examination
revealed as follows: hemoglobin 11 g/dL, serum crea-
tinine 3.04 mg/dL (estimated GFR by Modification of
Diet in Renal Disease equation 15.7 mL/min/1.73m2),
blood urea nitrogen 41.8 mg/dL, potassium 4.5 mmol/
L, chloride 65 mmol/L, bicarbonate 24 mmol/L, calcium
8.0 mg/dL, uric acid 5.7 mg/dL, total protein 5.8 g/dL,
albumin 3.6 g/dL, plasma glucose 88 mg/dL, chole-
sterol 229 mg/dL and triglyceride 79 mg/dL. Calculated
osmolality was 223.8 mOsm/kg and osmolar gap was
5.8 mOsm/kg, precluding the possibility of pseudohy-
ponatremia.
Endocrine hormone examination showed normal
cortisol level and euthyroid status. Plasma antidiuretic
hormone (ADH) was 10.65 pg/mL (normal, 0-6.7 pg/
mL), despite the presence of severe hyponatremia.
The patient denied of any overzealous fluid intake or
herb medication use.
Symptomatic hyponatremia precipitated by oral CY
was suspected in view of decreased serum sodium
level, inappropriately high urine osmolality and chro-
nologic association with CY administration.
After admission, free water intake was restricted
and the patient was treated with intravenous hyper-
tonic saline and injections of furosemide. Her consci-
ousness fully recovered after 12 hours and hypertonic
saline and intravenous furosemide administrations were
continued for 3 more days to correct her serum sodium
Fig. 1. Chest X-ray taken 3 weeks before (A) and on the day of emergency depart-
ment admission (B). Chest X-ray shows no signs of pulmonary edema or
significant decrease of heart size.
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level up to 131 mmol/L (Fig. 2). Thereafter she was
treated conservatively with 0.9% saline 1 L/day for
4 more days. She was discharged 10 days after ad-
mission. It remains unknown whether the treatment
with oral CY can be safely reinstituted after an episode
of acute hyponatremia. Therefore, the patient was
switched to oral mycophenolatemofetil (2 g/day) and
steroids. She has not experienced any more electrolyte
derangements.
DISCUSSION
The case presented here highlights the possible
dangers of oral CY therapy in precipitating life threa-
tening acute hyponatremia. CY is a commonly used drug
in the treatment of various autoimmune or malignancy
disorders. However, there are some serious adverse
effects associated with the use of this agent including
bone marrow suppression, bladder cancer and hypo-
natremia2). High doses of intravenous CY (>50 mg/kg)
have been clearly demonstrated to impair kidney s’
ability to dilute urine. Recently, low-dose (<15 mg/kg)
intravenous pulse CY treatments are predominant re-
gimen used in the clinical practice. This low dose CY
may reduce the risk of water intoxication but the risk
of precipitating symptomatic hyponatremia is not un-
common3). In contrast, symptomatic hyponatremia
associated with low dose oral CY treatment has rarely
been reported. To the best of our knowledge, there
is only one other case of symptomatic hyponatremia
associated with low dose oral CY treatment (1.4 mg/
kg)1). The present case demonstrated development
of symptomatic hyponatremia after 3 weeks of oral
CY treatment that was initially well tolerated.
The precise mechanism of CY induced hyponatremia
remains uncertain. Direct toxic effects or potentiation
of the renal action of ADH by alkylating metabolites
of CY have been proposed2, 4). Mildly elevated plasma
ADH level noted in our patient might more likely be
due to decreased urinary clearance of ADH in chronic
renal failure as opposed to increased secretion by
accompanying mild volume depletion8). Moreover, some
lines of evidence argue against dehydration as the
major player in causing the severe hyponatremia
noted in the patient. The patient was not hypotensive
and did not show any signs of tachycardia that are
Fig. 2. Changes in the serum sodium level during hospitalization. Hypertonic saline
was administrated for first 3 days and replaced with normal saline. Her men-
tality was fully recovered 12 hours after hypertonic saline infusion. Intravenous
hydration was continued for 7 days and she was discharged on 10
th
day of
hospitalization.
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commonly observed in patients with volume depletion.
Furthermore, the ratio between blood urea nitrogen
and serum creatinine (13.7) nor calculated FENa de-
monstrated by the patient were compatible with severe
dehydration.
Onset of clinically symptomatic hyponatremia was
most common within 1-2 days of intravenous CY ad-
ministration2). Due to the paucity of reported cases of
symptomatic hyponatremia after oral administration of
CY, the time frame of development of symptomatic
hyponatremia is uncertain. Compared to intravenous
route, the oral route of administration might take more
time for the metabolites of CY to accumulate in the
body. As is in our case, the underlying renal impair-
ment might have contributed to greater accumulation
of drug metabolites and could have triggered the de-
velopment of severe hyponatremia.
Previously reported cases of severe hyponatremia
associated with low dose CY treatment were usually
preceded by massive hydration (2-3 L/day)3). Our
patient denied any overzealous water intake but did
report daily fluid intake of at least 1 liter. The patient
denied taking any medications such as non-steroidal
anti-inflammatory agents or thiazide diuretics that
may provoke acute hyponatremia. The rapid improve-
ment of hyponatremia after cessation of CY also sup-
port the role of CY in development of hyponatremia.
Taken together, the progressive accumulation of CY
metabolites and possible fluid retention due to patient s’
underlying impaired renal function could have aggra-
vated hyponatremia.
Treatment for acute hyponatremia usually consists
of removal of the inciting factor and infusion of hy-
pertonic or isotonic saline5). The CY treatment was
stopped immediately and our patient received hyper-
tonic saline and loop diuretics. She showed dramatic
neurologic improvements within the first 24 hours and
her electrolyte abnormalities improved after conserva-
tive treatment.
The present case illustrates the potential danger of
acute hyponatremia following low dose oral CY treat-
ment. Two other cases of acute symptomatic hypo-
natremia after low dose and moderate dose of intra-
venous cyclophosphamide have been reported in
Korea6, 7). Lee et al also reviewed water intoxication
after low dose intravenous CY, which were usually
associated with massive intravenous hydration to pre-
vent development of hemorrhagic cystitis3). To the
best of our knowledge, the present case is the first
case report of acute symptomatic hyponatremia after
low dose of oral CY in Korea. Greater awareness of
this potentially life-threatening complication may re-
duce the risk of its occurrence.
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